RISK FOR HERPES ZOSTER AFTER TREATMENT WITH BIOLOGIC AND SYNTHETIC DISEASE MODIFYING AGENTS FOR RHEUMATOID ARTHRITIS

被引：0
|
作者：
Pappas, D. A. [1 ]
Hooper, M. [2 ]
Reed, G. [3 ]
Shan, Y. [3 ]
Wenkert, D. [2 ]
Zhang, J. [4 ]
Greenberg, J. [5 ]
Curtis, J.
机构：
[1] Columbia Univ, New York, NY USA
[2] Amgen Inc, Thousand Oaks, CA USA
[3] Univ Massachusetts, Med Ctr, Worcester, MA USA
[4] Univ Alabama Birmingham, Birmingham, AL USA
[5] NYU, Langone Med Sch, New York, NY USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 71卷
关键词：
D O I：
10.1136/annrheumdis-2012-eular.2565
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：346 / 346
页数：1
相关论文
共 50 条
  • [1] Risks of Herpes Zoster in Patients With Rheumatoid Arthritis According to Biologic Disease-Modifying Therapy
    Yun, Huifeng
    Xie, Fenglong
    Delzell, Elizabeth
    Chen, Lang
    Levitan, Emily B.
    Lewis, James D.
    Saag, Kenneth G.
    Beukelman, Timothy
    Winthrop, Kevin
    Baddley, John W.
    Curtis, Jeffrey R.
    ARTHRITIS CARE & RESEARCH, 2015, 67 (05) : 731 - 736
  • [2] Risk of Herpes Zoster in Patients with Rheumatoid Arthritis Treated with Biologic Disease-Modifying Therapy Compared with Conventional Therapy
    Kwon, Hyun Mi
    Lee, Sang Jin
    Yang, Ji Ae
    Moon, Jin Young
    Ahn, Eun Young
    Park, Jin Kyun
    Lee, Eun Young
    Song, Yeong Wook
    Lee, Eun Bong
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [3] Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence
    Singh, Namrata
    Li, Christopher, I
    CURRENT OPINION IN RHEUMATOLOGY, 2021, 33 (03) : 292 - 299
  • [4] Medicare expenditures for conventional and biologic disease modifying agents commonly used for treatment of rheumatoid arthritis
    Dalal, Deepan S.
    Zhang, Tingting
    Shireman, Theresa, I
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020, 50 (05) : 822 - 826
  • [5] RISK OF HERPES ZOSTER IN PATIENTS WITH RHEUMATOID ARTHRITIS UNDER BIOLOGICAL, TARGETED SYNTHETIC, AND CONVENTIONAL SYNTHETIC DMARD TREATMENT
    Strangfeld, A.
    Redeker, I.
    Kekow, J.
    Burmester, G. R.
    Braun, J.
    Zink, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 150 - 151
  • [6] Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register
    Redeker, Imke
    Albrecht, Katinka
    Kekow, Joern
    Burmester, Gerd Ruediger
    Braun, Juergen
    Schaefer, Martin
    Zink, Angela
    Strangfeld, Anja
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (01) : 41 - 47
  • [7] Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster
    Yamaoka, Kunihiro
    DRUG SAFETY, 2016, 39 (09) : 823 - 840
  • [8] Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster
    Kunihiro Yamaoka
    Drug Safety, 2016, 39 : 823 - 840
  • [9] Biologic agents in the treatment of rheumatoid arthritis
    Hasegawa, Hitoshi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2014, 124 : 67P - 67P
  • [10] Biologic agents for the treatment of rheumatoid arthritis
    Strand, V
    Keystone, E
    Breedveld, F
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1996, 22 (01) : 117 - &
12345